Aratana Therapeutics, Inc. (PETX)
(Delayed Data from NSDQ)
$4.75 USD
+0.11 (2.37%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.75 USD
+0.11 (2.37%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Aratana (PETX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aratana (PETX) delivered earnings and revenue surprises of -40.00% and 5.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Aratana (PETX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Aratana (PETX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aratana (PETX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aratana (PETX) delivered earnings and revenue surprises of -63.64% and -24.82%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Aratana Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Aratana Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Aratana Therapeutics (PETX) in Focus: Stock Moves 6.8% Higher
by Zacks Equity Research
Aratana Therapeutics (PETX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Aratana (PETX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Aratana (PETX) delivered earnings and revenue surprises of 246.15% and 278.16%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Aratana (PETX) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Aratana (PETX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aratana (PETX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aratana (PETX) delivered earnings and revenue surprises of 26.32% and 3.98%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Drug Stocks Poised to Surpass on Earnings This Quarter
by Zacks Equity Research
The outlook for the upcoming first-quarter results looks bright.
Aratana Therapeutics (PETX) Soars: Stock Adds 12.4% in Session
by Zacks Equity Research
Aratana Therapeutics (PETX) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.
Is a Surprise Coming for Aratana Therapeutics (PETX) This Earnings Season?
by Zacks Equity Research
Aratana Therapeutics (PETX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod
by Zacks Equity Research
Eli Lilly (LLY) animal health unit Elanco and partner Aratana announce the EU approval of Galliprant for treatment of pain associated with osteoarthritis in dogs.
Intellipharmaceutics International (IPCI) Jumps: Stock Up 19%
by Zacks Equity Research
Intellipharmaceutics International Inc. (IPCI) shares rose around 19% in the last trading session.
Can Epizyme (EPZM) Spring a Surprise This Earnings Season?
by Zacks Equity Research
Epizyme, Inc. (EPZM) is scheduled to report fourth-quarter 2016 results on Mar 9, before the opening bell.
AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) is expected to report fourth-quarter 2016 results this month.
Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug
by Zacks Equity Research
Eli Lilly and Company's (LLY) animal health subsidiary, Elanco and partner Aratana Therapeutics, Inc. (PETX) together announced the availability of Galliprant for the management of pain and inflammation associated with canine osteoarthritis (OA).
Explosive Stocks Under $10
by Kevin Matras
Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include PETX, AKS, ARIA, LSG and PVG.